MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M

MaxCyte, Inc. (NASDAQ: MXCT) reported preliminary core revenue of approximately $8.1 million for Q3 2026, marking a 26% increase year-over-year. The company has raised its full-year 2026 revenue guidance to approximately $34 million, up from the previous estimate of $30 million to $32 million, with core business revenue expected to be around $28 million. Additionally, SPL Program-related revenue is projected at approximately $6 million, an increase from the prior guidance of $5 million.